Athos Capital’s Envoy Medical Warrant COCHW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19K Hold
28,588
– – 0.01% 31
2026
Q2
$23K Hold
28,588
– – 0.01% 35
2026
Q1
$19K Hold
28,588
– – 0.01% 39
2025
Q4
$19K Hold
28,588
– – 0.01% 34
2025
Q3
$22K Hold
28,588
– – 0.01% 32
2025
Q2
$41K Hold
28,588
– – 0.06% 32
2025
Q1
$37K Hold
28,588
– – 0.04% 38
2024
Q4
$45K Hold
28,588
– – 0.02% 36
2024
Q3
$105K Hold
28,588
– – 0.03% 33
2024
Q2
$67K Hold
28,588
– – 0.04% 37
2024
Q1
$114K Hold
28,588
– – 0.12% 39
2023
Q4
$52K Buy
+28,588
New +$772 0.06% 40
2023
Q3
– Sell
-33,332
Closed -$342K – 58
2023
Q2
$342K Hold
33,332
– – 0.27% 55
2023
Q1
$333K Hold
33,332
– – 0.23% 66
2022
Q4
$334K Hold
33,332
– – 0.19% 84
2022
Q3
$328K Hold
33,332
– – 0.14% 105
2022
Q2
$326K Hold
33,332
– – 0.12% 118
2022
Q1
$328K Hold
33,332
– – 0.12% 109
2021
Q4
$332K Hold
33,332
– – 0.1% 111
2021
Q3
$330K Hold
33,332
– – 0.08% 129
2021
Q2
$333K Buy
+33,332
New +$23.8K 0.07% 147

Other funds holding COCHW

Athos Capital's COCHW Position: Q3 2026 in Review

Athos Capital held its Envoy Medical Warrant (COCHW) position steady in Q3 2026 at 28,588 shares worth $19K. The position accounts for 0.01% of the portfolio, ranked #31.

Athos Capital first reported a position in COCHW in Q2 2021 and has held it in 21 quarters since. The position peaked at $342K in Q2 2023. 36 funds tracked by Wall St. Rank hold COCHW as of Q3 2026.

  • Athos Capital held 28,588 shares of Envoy Medical Warrant worth $19K as of Q3 2026.
  • Athos Capital left its Envoy Medical Warrant share count unchanged in Q3 2026.
  • Envoy Medical Warrant made up 0.01% of Athos Capital's portfolio in Q3 2026, its #31 holding.
  • Athos Capital first reported a position in Envoy Medical Warrant in Q2 2021 and has held it in 21 quarters since.
  • Athos Capital's Envoy Medical Warrant position peaked at $342K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held Envoy Medical Warrant as of Q3 2026.

Based on Athos Capital's 13F filing for Q3 2026, filed 13 Nov 2026.